Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study

The study protocol was reviewed and approved by institutional review boards at each study site [22]. The list of institutional review boards at each study site is provided in online resource. The study was conducted according to Good Clinical Practice and the Declaration of Helsinki guidelines. All the patients provided written informed consent, before undergoing study procedures.

Detailed study design has been described earlier [23]. The initial results of this study were presented at American Headache Society conference and the conference abstract was published [19]. Briefly, this study was a phase 3, multicenter, randomized, long-term, open-label study to assess the safety of galcanezumab 120 mg/month (with a loading dose of 240 mg) and 240 mg/month, for the treatment of episodic or chronic migraine. The study comprised of three study periods: (1) a 3- to 45-day screening period, (2) a 12-month open-label treatment phase, (3) a 4-month post-treatment period to observe the washout of the study drug. During the treatment phase, patients were randomized 1:1 to receive either 120 mg or 240 mg of subcutaneous galcanezumab once a month. Patients had to maintain a daily log of their headaches, migraine headaches and medications taken for treatment of acute episodes; this was reviewed at each monthly visit. Across the entire study, the first 3 months were clinical visits that took place at the investigator site, with both clinical (Months 6, 9, 12) and telephone visits (Months 4, 5, 7, 8, 10 and 11) at later months. During the post-treatment period, patients did not receive study medication but continued to maintain a log of their headache information and completed select patient-reported outcome measures [23].

The primary objective of the study was to evaluate the long-term safety and tolerability of galcanezumab (120 and 240 mg/month) for up to 1 year of treatment. Secondary objectives included efficacy measures such as change from baseline in number of monthly migraine headache days (MHD), headache days, frequency of medication use for acute treatment, patient’s global impression of illness/improvement, MSQv2.1 and MIDAS scores. Primary outcome and secondary efficacy outcomes that have been previously reported included improvement from baseline in MSQ RF-R domain and MIDAS total scores to month 12 [23]. This paper focuses on changes from baseline in the total score as well as each of the three domains of the MSQv2.1 for each collection point (Month 1–3, 6 and 12); and MIDAS total scores for each collection point (Month 3, 6, 9, 12) as well as changes from baseline for each item at month 12. In addition, the changes from baseline to post-treatment Months 14 and 16 for the MSQ Total and Domain scores, and Month 16 for MIDAS total scores were evaluated.

Patient population consisted of males and females aged 18–65 years, with a diagnosis of migraine as defined by International Classification of Headache Disorders [24] and with a migraine onset before age 50 years. Patients who had a frequency of ≥4 migraine headache days per month (on average during the past 3 months) and a history of at least one headache-free day per month for the past 3 months were included in the study. Patients with a prior exposure to galcanezumab; use of any therapeutic antibody in the past 12 months; currently receiving medication or other treatments for prevention of migraine; history of failure to respond to three or more classes of migraine preventive treatments; history of headache other than migraine; history of traumatic head injury; recent history of acute cardiovascular events or history of stroke were excluded. Patients with concurrent tension-type headache or medication overuse headache were eligible to participate in the study.

MSQv2.1 is a self-administered health-related quality of life status instrument that was developed to specifically address the effect of migraine on work or daily activities, relationships with family and friends, leisure time, productivity, concentration, energy, tiredness and feelings. The instrument consists of 14 items with three domain scores: Role Function-Restrictive (RF-R), Role Function-Preventive (RF-P) and Emotional Function (EF). RF-R has seven items that measure the impact of migraine on limiting individual’s social and work-related activities. RF-P has four items that measure the degree to which migraine prevents the performance of usual activities. EF has three items that measure the impact of migraine on emotions. Response options range from “none of the time" to “all of the time,” and are reverse-recoded before the domain scores are calculated. The total raw scores for each domain are transformed to a 0 to 100 scale, with higher scores indicating better functional health status [20, 25]. The instrument was designed with a 4-week recall period, and is considered reliable, valid and sensitive to change in migraine [20, 25].

MIDAS is a patient-rated scale that quantifies migraine-related disability over a 3-month period. The instrument consists of five items that reflect the number of days reported as missed/absent or with reduced productivity at work/school or home, and the number of days with missed social events. Each item has a numeric response ranging from 0 to 90 days; the days which are missed from work or home are not counted as the days with reduced productivity at work or home. The total number of days for each item are added together to produce a total score, ranging from 0 to 270, in which a higher value is indicative of more disability. Defined categorical grades of disability include Grade 1: little or no disability (0–5), Grade II: mild disability (6–10), Grade III: moderate disability (11–20), Grade IVa: severe disability (21–40) and Grade IVb: very severe disability (41 +) [21, 26, 27]

The planned sample size for the study was approximately 250 patients. With the assumption of 20% dropout rate, this sample size was calculated to fulfill regulatory requirements of at least 100 patients with 1 year of exposure on each dose. The study was not powered to detect differences between two galcanezumab doses in any scales/questionnaire.

MSQ was measured at baseline and months 1, 2, 3, 6, 9 and 12 throughout the treatment period, and months 14, 16 in post-treatment period. MIDAS was measured at baseline and months 3, 6, 9 and 12 during the treatment period, and month 16 in post-treatment period. Changes from baseline in MSQv2.1 and MIDAS scores were analyzed using a restricted maximum likelihood-based mixed measures repeated model (MMRM), which included fixed categorical effects of treatment, treatment-by-visit interaction, pooled investigative site, visit, as well as the continuous fixed covariates of baseline and baseline-by-visit interaction. Analyses were conducted on an intent-to-treat basis, with patients analyzed according to assigned treatment group. P-values ≤ 0.05 were considered as statistically significant and 95% confidence intervals were provided.

Within-group improvements from baseline on MSQ individual domain scores and total score were statistically significant for the GMB 120 mg and GMB 240 mg at all-time points during the treatment phase. For MSQ individual domains, significant within-group improvements (p < 0.001) were observed, with the greatest improvement being observed in the RF-R domain (Overall least squares (LS) mean change ± SE), 31.6 ± 1.2 (GMB 120 mg) and 33.4 ± 1.2 (GMB 240 mg) [23]. A similar trend was also observed with overall MSQ total scores during the treatment phase (28.3 ± 1.2 (GMB 120 mg) and 30.3 ± 1.1 (GMB 240 mg) [p < 0.001] (Table 2; Fig. 1). Overall LS mean change (SE) for MSQv2.1 individual domain scores and total score are summarized in Table 2.

Post-treatment LS mean changes in MSQ scores from month 12 to months 14 and 16 are summarized in Table 3 and Fig. 1. During the post-treatment phase, decrease in functioning was observed. At month 14, LS mean change ± SE from month 12 in MSQ total scores were: − 7.1 ± 1.7 (GMB 120 mg) and − 8.4 ± 1.6 (GMB 240 mg) [p < 0.001]. Similarly, at month 16, LS mean change ± SE from month 12 in MSQ total scores were: − 8.1 ± 1.8 (GMB 120 mg) and − 9.6 ± 1.7 (GMB 240 mg) [p < 0.001]. Table 3 summarizes LS mean changes in individual domain scores at month 14 and 16.

The within-group mean improvement from baseline on MIDAS total scores and the individual item scores were statistically significant (p < 0.001) for GMB 120 mg and GMB 240 mg groups, with changes ranging from very severe to a moderate or nearly moderate level of disability. Across the 12-month treatment phase, the overall LS mean change ± SE from baseline in total scores were: − 33.6 ± 2.1 (GMB 120 mg) and − 32.7 ± 2.0 (GMB 240 mg) (Table 2; Fig. 2) [23]. Individual item scores are summarized in Fig. 2.

At month 16 (5 months after treatment was stopped), increase in disability was observed; LS mean change ± SE from Month 12 in MIDAS total scores were: 7.3 ± 3.8 (GMB 120 mg) and 11.8 ± 3.4 (GMB 240 mg) [p < 0.001] (Table 3, Fig. 2).

The overall reduction from baseline in the mean MHD with GMB 120 mg and 240 mg during the 12-month treatment phase has been previously reported [23]. The overall reduction from baseline in the mean MHD for GMB 120 mg and 240 mg during the 12-month treatment phase and post-treatment phase is presented in Fig. 3. During the post-treatment phase, LS mean change ± SE from baseline in MHD were: − 4.5 ± 0.5 (GMB 120 mg) and -5.3 ± 0.5 (GMB 240 mg) [p < 0.001] at Month 14 and − 4.8 ± 0.5 (GMB 120 mg) and − 5.4 ± 0.5 (GMB 240 mg) [p < 0.001] at Month 16 (Fig. 3). While the within-group reductions were statistically significant throughout the treatment and post-treatment phases (p < 0.001), the magnitude of the reductions decreased during the post-treatment phase relative to treatment phase.

The study findings suggest that treatment with galcanezumab (120 mg or 240 mg), among patients with episodic and chronic migraine (≥ 4 migraine headache days per month) resulted in statistically significant and meaningful reductions in disability and improvements in health-related quality of life. These improvements were observed at month 1 and continued through month 12. At baseline, MSQv2.1 RF-R scores were less than 50, indicating considerable functional restrictions due to migraine on work and daily activities. Overall, treatment with galcanezumab up to 12 months resulted in increase of RF-R LS mean scores by 31.6–33.4 points, with significant changes from baseline scores observed as early as month 1. By month 12, the observed changes resulted in nearly 80% of the total score possible for the RF-R domain, translating into more fully functional time across work and daily activities. Similar results were observed across the other two domains which evaluated the degree to which migraine prevents the performance of daily activities and the emotional impairment associated with migraine (RF-P and EF), and for the MSQv2.1 total score that reflects improvement in overall health-related quality of life. These results indicated that galcanezumab was effective in reducing functional impairment due to migraine on work or daily activities, relationships with family and friends, leisure time, productivity, concentration, energy, tiredness and feelings beginning at month 1 and continuing through month 12.

At baseline, the study population was very severely disabled due to migraine per the MIDAS total score, and patients were absent from work/school approximately 5–7 days on average over the 3 months prior to randomization. In addition, loss of productivity was reported in nearly twice as many days (approximately 9–12 days); missed household work and productivity loss ranged from approximately 11–13 days, and family/social events were missed ~ 7 to 9 days over the prior 3 months. Over months 1–12, the level of disability (measured as LS mean change in MIDAS total score) due to migraine significantly reduced by 33.6–32.7 days, resulting in a population that had moderate to nearly moderate disability. Notably, absences and productivity losses for work/school over the last 3 months of the study were reduced by 50%. Similar or even greater reductions were observed for household work and social events.

The findings of this study are important, as the effects of galcanezumab on functional impairment and disability have only been evaluated for a duration of 6 months in patients with episodic migraine [17, 18]. The chronic migraine phase 3 study consisted of a 3-month double-blind placebo controlled phase followed by a 9-month open-label treatment phase with flexible dosing [28]. The results from our study are specific to an equal randomization to 120 mg and 240 mg doses for a full duration of 12 months in an open-label study with less frequent clinical site visits. Given that a stated treatment goal for preventive therapy is a reduction in disability and improvement in patient functioning and health-related quality of life, these galcanezumab findings that are specific to a 12-month period are clinically relevant. In addition, during the post-treatment follow-up phase, the improvement in patient’s health-related quality of life and disability decreased over time; however, the effects did remain which is expected with the half-life of the drug. These effects during post-treatment phase were consistent with previous studies [29].

Regarding similar CGRP studies, comparisons between studies are limited by differences in methodologies. The results from a phase 2 open-label extension erenumab study in patients with episodic migraine reported MSQ and MIDAS improvements from baseline for patients who had completed the 1-year open-label extension period. A decrease in approximately 15 points for the total MIDAS score and improvements of approximately 23 points for MSQ RF-R were observed [30]. Regarding chronic migraine, the efficacy of onabotulinumtoxinA was evaluated in a long-term open-label Phase IV trial, changes in how often headaches interfered with activities or caused distress was evaluated via the Headache Impact Test-6 ™ (HIT-6), demonstrating significant improvements with long-term use [31]. Overall, preventive treatments with acceptable levels of evidence per treatment guidelines are recognized as having the potential to reduce disability and improve patient functioning [9, 14].

As the results of this phase 3 open-label clinical study are clinically relevant, there are limitations that are worth noting. The study was not designed to evaluate the magnitude of improvement versus a comparator, or between the two dose groups of galcanezumab. The number of countries where the study was conducted in was limited; therefore, the results may not be generalizable to populations across all countries. Strengths include the use of valid and reliable patient-reported instruments that are disease specific to measure disability and health-related quality of life associated with migraine. Recall bias with the MIDAS could be seen as a confounder; however, psychometric research has demonstrated that the 90-day recall is valid and reliable, and scores are recognized as being correlated with clinical judgment as related to the need for medical care and the level of disability [26]. In addition, as this is an open-label study without placebo group, the placebo response rates that could affect the study are not considered.

These results provide important evidence for clinicians, that observed decreases in disability and improvements in health-related quality of life when treated with galcanezumab (120 mg or 240 mg) occur rapidly and are sustained over 12 months among patients with episodic and chronic migraine.